What is HC Wainwright’s Estimate for ATNM Q1 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.35) EPS and Q4 2025 earnings at ($0.39) EPS.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $1.49 on Wednesday. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The stock has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.44. The company has a market capitalization of $46.48 million, a P/E ratio of -1.07 and a beta of 0.10.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Actinium Pharmaceuticals by 3.0% in the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after buying an additional 19,843 shares during the last quarter. Northern Trust Corp increased its position in shares of Actinium Pharmaceuticals by 4.9% in the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after purchasing an additional 11,812 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Actinium Pharmaceuticals by 25.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after purchasing an additional 42,770 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Actinium Pharmaceuticals by 49.9% during the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in Actinium Pharmaceuticals by 25.4% in the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock worth $231,000 after purchasing an additional 37,159 shares in the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).